The Enterprise Value as of December 2025 (TTM) for Recursion Pharmaceuticals, Inc. (RXRX) is 1.53B

According to Recursion Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.53B. This represents a change of -8.62% compared to the average of 1.68B of the last 4 quarters.

Recursion Pharmaceuticals, Inc. (RXRX) Historical Enterprise Value (quarterly & annually)

How has RXRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Recursion Pharmaceuticals, Inc. over the last ten years is 2.04B. The current 1.53B Enterprise Value has changed 7.41% with respect to the historical average. Over the past ten years (40 quarters), RXRX's Enterprise Value was at its highest in in the June 2021 quarter at 5.53B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Recursion Pharmaceuticals, Inc. (RXRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Recursion Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Recursion Pharmaceuticals, Inc. (RXRX) Average Enterprise Value

How has RXRX Enterprise Value performed in the past?

The current Enterprise Value of Recursion Pharmaceuticals, Inc. (RXRX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Recursion Pharmaceuticals, Inc. (RXRX) Enterprise Value vs. Peers

How is RXRX’s Enterprise Value compared to its peers?

Recursion Pharmaceuticals, Inc.’s Enterprise Value is less than Agios Pharmaceuticals, Inc. (1.55B), less than Denali Therapeutics Inc. (2.90B), less than 89bio, Inc. (2.11B), less than Beam Therapeutics Inc. (2.82B), less than ImmunityBio, Inc. (2.24B), less than Arcus Biosciences, Inc. (2.59B), less than Cogent Biosciences, Inc. (5.53B), less than Sarepta Therapeutics, Inc. (2.87B), less than Galapagos N.V. (1.73B), less than Liquidia Corporation (2.94B),

Build a custom stock screener for Recursion Pharmaceuticals, Inc. (RXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Recursion Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Recursion Pharmaceuticals, Inc. (RXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Recursion Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.